Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - insuliini glargine, lixisenatide - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - kolorektaalne kasvaja - antineoplastilised ained - metastaatilise kolorektaalse vähi (mcrc) ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artriit, reumatoidartriit - immunosupressandid - kevzara kombinatsioonis metotreksaadiga (mtx) on näidustatud mõõduka kuni raske aktiivse reumatoidartriidi (ra) täiskasvanud patsientidel, kes reageerisid ebapiisavalt või kes ei talu ühe või enama haigust modifitseeriva anti reumaatiliste käsitlemine (hmr). kevzat võib mtx-ga talumatuse korral monoteraapiana anda või kui mtx-ravi ei sobi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - insuliin lispro - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõvega täiskasvanute ja laste raviks, kes vajavad insuliini normaalse glükoosi homöostaasi säilitamiseks. insuliin lispro sanofi on näidustatud ka suhkurtõve esialgseks stabiliseerimiseks.

Eesti - eesti - Ravimiamet

sanofi-aventis deutschland gmbh - lühikese toimeajaga ja keskmise toimeajaga humaaninsuliin - süstesuspensioon - 100rÜ 1ml 3ml 10tk; 100rÜ 1ml 3ml 6tk; 100rÜ 1ml 3ml 3tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil+hüdroklorotiasiid - tablett - 5mg+25mg 28tk; 5mg+25mg 56tk; 5mg+25mg 14tk; 5mg+25mg 300tk; 5mg+25mg 30tk; 5mg+25mg 98tk; 5mg+25mg 99tk; 5mg+25mg 50tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil - tablett - 5mg 50tk; 5mg 18tk; 5mg 45tk; 5mg 300tk; 5mg 14tk; 5mg 90tk; 5mg 98tk; 5mg 99tk; 5mg 10tk; 5mg 15tk; 5mg 30tk; 5mg 100tk

Eesti - eesti - Ravimiamet

sanofi-aventis deutschland gmbh - lühikese toimeajaga ja keskmise toimeajaga humaaninsuliin - süstesuspensioon - 100rÜ 1ml 3ml 3tk; 100rÜ 1ml 3ml 4tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil+hüdroklorotiasiid - tablett - 10mg+12,5mg 30tk; 10mg+12,5mg 28tk; 10mg+12,5mg 60tk; 10mg+12,5mg 56tk; 10mg+12,5mg 100tk; 10mg+12,5mg 10tk